Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
GLP-1 drugs and knee replacement risk
A large retrospective study ties GLP-1 receptor agonist use to lower rates of knee replacement surgery for osteoarthritis.
GLP-1 drugs cut CV risk in type 2 diabetes
A 2026 network meta-analysis finds GLP-1 therapies reduce mortality and MACE in type 2 diabetes. Semaglutide and albiglutide rank highest.
GLP-1 drugs and hair loss: the data
Hair loss affects roughly 4% of GLP-1 receptor agonist users. The likely cause is rapid weight loss triggering telogen effluvium, not direct follicle damage.
GLP-1 drugs tied to lower heart risk in RA
A TriNetX cohort study found GLP-1 therapy halved heart failure and respiratory failure risk in non-diabetic adults with RA and obesity.
Do GLP-1 drugs reduce fat graft survival?
A scoping review flags several mechanisms through which GLP-1 receptor agonists may reduce fat graft survival. No clinical data exist yet.
Ipamorelin 3x a day: what the evidence says
No human trial has tested a three-times-daily ipamorelin protocol. Here is where the idea comes from and what is missing from the evidence.
IWQOL-Lite-CT: trial vs real-world scores
Real-world adults with obesity score far worse on the IWQOL-Lite-CT than STEP 1 semaglutide trial participants. The instrument works, but baselines differ.
Microdosing tirzepatide: what we know
No trial has tested tirzepatide below 2.5 mg. A 2026 Obesity commentary examines the growing practice of KwikPen microdosing.
Oral semaglutide dropout rates in Japan
A Japanese database study found that high HbA1c and concurrent metformin use predicted early discontinuation of oral semaglutide at the 3 mg starting dose.
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
Semaglutide at 6 months: STEP trial data
Community posts report 80-90 lbs lost in six months on semaglutide. Here is what STEP trial data shows about timelines and plateaus.
Semaglutide in teens: who responds best?
A real-world study asks which adolescents respond best to semaglutide for obesity, moving beyond the STEP TEENS trial into clinical practice.